NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-HL-23-017 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA), seek highly meritorious clinical trial applications proposing to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project (RMIP), represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act. Applications submitted in response to this bi-phasic, milestone-driven cooperative agreement FOA are expected to propose highly innovative projects with a focus on solutions to widely-recognized issues in the development of safe and effective RM therapies. Of particular interest are projects using RM products that have undergone appropriate product development and pre-clinical studies and have demonstrated readiness to advance into clinical trials. This FOA seeks Phase I and beyond clinical trial applications that present a strong scientific rationale for the proposed clinical trial and a comprehensive scientific and operational plan. Trials must be relevant to the research mission of one or more participating NIH Institutes and Centers and meet the NIH definition of a clinical trial (see NOT-OD-15-015). Applications will be required to include plans for project management, participant recruitment and retention, performance milestones, conduct of the trial, and dissemination of results. Before the time of award and if applicable, successful applicants must obtain an Investigational New Drug (IND) authorization or Investigational New Device Exemption (IDE) approval to administer the product to humans.
Notice NOT-CA-22-102 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-213 from the NIH Guide for Grants and Contracts. This FOA allows for applications that propose large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to aging. Such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions.
Notice NOT-HL-22-027 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HL-23-015 from the NIH Guide for Grants and Contracts. The purpose of the initiative is to utilize the cohort study design to address key population research gaps in the health of Asian Americans (AsA), Native Hawaiians, and Pacific Islanders (NHPI). This FOA is for clinical/community field centers (CCFCs), and a companion one will solicit for the coordinating center (CC).
Funding Opportunity RFA-HL-23-016 from the NIH Guide for Grants and Contracts. The purpose of the initiative is to utilize the cohort study design to address key population research gaps in the health of Asian Americans (AsA), Native Hawaiians, and Pacific Islanders (NHPI). This FOA is for the coordinating center (CC), and a companion one will solicit for clinical/community field centers (CCFCs).
Notice NOT-GM-22-036 from the NIH Guide for Grants and Contracts
Notice NOT-GM-22-040 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-157 from the NIH Guide for Grants and Contracts
Notice NOT-AG-22-025 from the NIH Guide for Grants and Contracts
Notice NOT-MH-22-235 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-171 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-209 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications for the early-stage development of therapeutics to mitigate the adverse health effects resulting from toxic chemical exposure. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include specific chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The overall scope of this solicitation includes validation of therapeutic targets and preclinical characterization of lead compounds. The UG3 phase of this FOA supports target validation and characterization of initial lead compound(s); UH3 phase activities include candidate optimization and in vivo demonstration of activity and efficacy in relevant post-exposure models. At the conclusion of the overall UG3/UH3 funding period, projects are expected to deliver at least one well-characterized therapeutic candidate.
Notice NOT-OD-22-170 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-174 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-169 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-173 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-172 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-23-046 from the NIH Guide for Grants and Contracts. This FOA solicits applications for multi-disciplinary RM1 Research Centers (RM1s) that involve partnerships between researchers and payors, health plans, single state agencies/opioid treatment authorities, professional organizations, or other entities. Relevant partners have a deployed or in-development quality measurement and management strategy or system that does or could inform provider or clinician selection and treatment improvement and that rigorous research could substantially advance. Activities should also support the acceptability of the quality measurement and management system to patients, clinicians, and providers; the feasibility, scalability, and sustainability of the system; and equity in quality provider selection and treatment delivery.
Notice NOT-HL-22-036 from the NIH Guide for Grants and Contracts